P/E ratio for Titan Pharmaceuticals (TTNP)
P/E ratio as of May 2024 (TTM): -11.8
According to Titan Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.7544. At the end of 2022 the company had a P/E ratio of -1.01.
P/E ratio history for Titan Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.01 | -10.62% |
| 2021 | -1.13 | 87.47% |
| 2020 | -0.6045 | 208.22% |
| 2019 | -0.1961 | -71.78% |
| 2018 | -0.6950 | -64.72% |
| 2017 | -1.97 | -112.73% |
| 2016 | 15.5 | -291.77% |
| 2015 | -8.07 | -53.94% |
| 2014 | -17.5 | -466.65% |
| 2013 | 4.78 | -203.83% |
| 2012 | -4.60 | 4.53% |
| 2011 | -4.40 | -63.15% |
| 2010 | -12.0 | -48.48% |
| 2009 | -23.2 | |
| 2007 | -4.12 | -48.16% |
| 2006 | -7.94 | 281.42% |
| 2005 | -2.08 | -46.58% |
| 2004 | -3.90 | 42.16% |
| 2003 | -2.74 | 92.75% |
| 2002 | -1.42 | -90.91% |
| 2001 | -15.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -190.55% | 🇺🇸 USA |
 Novartis NVS | 26.0 | -321.42% | 🇨🇭 Switzerland |
 Vanda Pharmaceuticals VNDA | 17.3 | -247.46% | 🇺🇸 USA |
 Repligen
RGEN | 79.6 | -776.97% | 🇺🇸 USA |
 MediciNova MNOV | -5.52 | -53.04% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -17.0 | 44.84% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.